乐虎国际娛乐

English
banner
Products
Home

Herbal Extract

IVY LEAF EXTRACT

IVY LEAF EXTRACT

nsf-GMP , HACCP , Kosher , HALAL
  • Product Details

Product Information


Product name

Ivy Leaf Extract

Hederacoside C ; Hederacosides ; Hederagenin

Specification

(1) 1%-20% Hederacoside C (by HPLC)

(2) 10%-80% Hederacosides (by HPLC)

(3) 5%-10% Hederagenin (by HPLC)

(4)10:1 (TLC)

Particle Size

100% pass 80 mesh

Extraction solvent

Ethanol & water

Certification

Nsf-GMP / ISO / HACCP / Kosher / HALAL

Appearance

Fine Brownish powder


COA of Ivy leaf Extract


Items

Specification

Results

Physical control

Identification

Positive

Complies

Loss on drying

Not more than 5.0%

4.0%

Appearance

Brown powder

Conforms

Odor

Characteristic

Conforms

Taste

Characteristic

Conforms

Particle size

100% through 80 mesh

Conforms

Ash

Not more than 5.0%

3.75%

Impurities control

Heavy metals

Not more than 10ppm

Conforms

Arsenic(As)

Not more than 1ppm

Conforms

Lead(Pb)

Not more than 1ppm

Conforms

Cadmium(Cd)

Not more than 0.5ppm

Conforms

Hg

Not more than 0.5ppm

Conforms

Cu

Not more than 0.5ppm

Conforms

Microbiological control

Total plate count

Not more than 1000cfu/g

Conforms

Salmonella

Negative

Conforms

Yeast & Mold

Not more than 100cfu/g

Conforms

E. Coli

Negative

Conforms

Conclusion

All the testing data meet the established specification.



Usage


Ivy leaf extract alleviates bronchitis and helps patients with asthma. Bronchitis and asthma are different diseases, but they have one feature in common-in both conditions the mucous membranes of the airways produce large amounts of phlegm or mucus and this hinders breathing. If the bronchi are narrowed further still by inflammation the patient may even become short of breath. Scientific investigations have shown that a special extract from IVY leaves can give definite relief from such symptoms, without any risk of the adverse side effects which may be associated with certain therapeutic agents of chemical origin. In a large scale clinical trial comprising 99 adults between 25 and 70 years of age with acute or chronic bronchitis the efficacy of IVY extract was compared under double-blind conditions with that of Ambroxol. The phytopharmaceutical was just as effective as the chemical drug.


Function:

(1)Ivy has the treatment of joint pain and lower back pain;
(2)Ivy can effectively resist to carcinogenic substances in the nicotine;
乐虎国际娛乐 (3)Ivy has the function of promoting blood circulation and detoxification.


Application:

(1)Applied in health product field, to protect liver kidney with excellent results;
(2)Applied in pharmaceutical field, It has certain effect for the treatment of fatty liver;
(3)Applied in cosmetic field, it is also referred as wash hair products, with the function of germinal hair play.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

ECHINACEA PURPUREA EXTRACT Supplier -Sinoway
ECHINACEA PURPUREA EXTRACT
Phenols ≥ 4% , USP42
RHODIOLA ROSEA EXTRACT Supplier -Sinoway
RHODIOLA ROSEA EXTRACT
Salidroside 3-5%, Rosavins 3-5%, Rosavin 2% up
GINKGO BILOBA EXTRACT
GINKGO BILOBA EXTRACT 90045-36-6
USP, EP, CP, 36/10=Flavone 36%+ Lactones 10%
ARTEMISIA ARGYI EXTRACT Supplier -Sinoway
ARTEMISIA ARGYI EXTRACT
Isocyanine 0.8%-2.4%; Chamomile 0.25%-0.75%
AZILSARTAN
AZILSARTAN 147403-03-0
99% up, JP/ GMP / PMDA / DMF
glutathione
L-GLUTATHIONE REDUCED (GSH) 70-18-8
L-GLUTATHIONE REDUCED (GSH) 70-18-8
MINOXIDIL
MINOXIDIL 38304-91-5
GMP , USP, Cosmetic Grade
LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

home

products

about

contact

乐优彩票登入,备用,官方网址 乐优彩票天天红单下载 乐优彩票网址是多少 乐优炫彩app 乐优炫彩app下载 乐博彩票官方app 乐优炫彩官网 乐优炫彩彩票app下载 乐体育app下载 乐善彩票网址